Key Facts Pfizer said it had evaluated several once-daily formulations of danuglipron and selected its preferred one to move forward to mid-stage trials with
In the context of shared mechanistic pathways relevant to thyroidbrain interactions, these data remain biologically informative, yet they also highlight a critical gap in thyroid-specific primary research
In a double-blind, parallel-group trial, the researchers randomly assigned 72 obese people to receive semaglutide or placebo
Never use methylene blue from non-pharmaceutical sources for self-medication
Semaglutide was associated with a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety and a 47% lower risk of worsening substance use disorder
In addition, approximately 1 in 3 participants (31.6%) who received cagrilintide achieved a weight loss 15%, compared to approximately 1 in 20 participants (4.7%) who received placebo